Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 4/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL610397 | 0.94 | FASN (0.43) | FASNDDB1CRBNGRM5CDK4 | |
| SCHEMBL610903 | 0.89 | FASN (0.43) | FASNDDB1CRBNBTKCDK4 | |
| SCHEMBL612067 | 0.88 | DDB1 (0.51) | DDB1CRBNLMNATP53MAPT | |
| SCHEMBL610780 | 0.88 | DDB1 (0.51) | DDB1CRBNLMNATP53MAPT | |
| SCHEMBL610349 | 0.88 | DDB1 (0.51) | DDB1CRBNLMNATP53MAPT | |
| SCHEMBL607847 | 0.87 | CDK6 (0.41) | FASNBTKCDK4CCND1 | |
| SCHEMBL610863 | 0.87 | CDK6 (0.41) | FASNBTKCDK4CCND1 | |
| SCHEMBL611366 | 0.87 | CDK6 (0.41) | FASNBTKCDK4CCND1 | |
| SCHEMBL609068 | 0.85 | CDK4 (0.45) | FASNBTKCDK4CCND1 | |
| SCHEMBL627707 | 0.84 | TYK2 (0.36) | FASNDDB1CRBNBTKCDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940741-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2603500-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8481540-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2603500-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012020008-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | FASN 4211/4885DDB1 1288/4885CRBN 825/4885 |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | FASN 4211/4885DDB1 1288/4885CRBN 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.